Postępowanie w nietrzymaniu moczu u kobiet z pęcherzem nadaktywnym w codziennej praktyce urologa Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2021
Słowa kluczowe:
mirabegron, agonista receptora β3-adrenergicznego, farmakoterapia, pęcherz nadaktywny, nietrzymanie moczu u kobiet
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nietrzymanie moczu powszechnie występuje wśród kobiet i istotnie przyczynia się do obniżenia jakości ich życia. Dostępnych jest wiele skutecznych metod leczenia najczęstszych rodzajów nietrzymania moczu (wysiłkowego, związanego z parciem naglącym i mieszanego) w formie modyfikacji stylu życia, technik behawioralnych, farmakoterapii i procedur małoinwazyjnych. Większość kobiet odnosi korzyść po zastosowanym leczeniu, a nietrzymanie moczu nie musi być nieuniknioną częścią procesu starzenia. Aby zmaksymalizować szanse na skuteczne leczenie, kluczowe jest dostosowanie podejścia terapeutycznego do celów i oczekiwań pacjenta oraz ocena potencjalnych skutków ubocznych, kosztów i spodziewanych korzyści. Istnieje wiele wyzwań związanych z leczeniem nadaktywnego pęcherza u starszych kobiet, takich jak: zaburzenia czynnościowe i poznawcze, choroby współistniejące, polipragmazja, niedobór estrogenów, które należy wziąć pod uwagę przy wyborze optymalnej terapii. Niniejszy przegląd przedstawia obecną wiedzę na temat związanych z wiekiem zmian w funkcjonowaniu pęcherza i proponuje rozwiązania kliniczne w postępowaniu z pęcherzem nadreaktywnym u starszych pacjentek.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wiatr , T., & Chłosta , P. (2021). Postępowanie w nietrzymaniu moczu u kobiet z pęcherzem nadaktywnym w codziennej praktyce urologa. Medycyna Faktów , 14(2(51), 169-175. https://doi.org/10.24292/01.MF.0221.5
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation sub-committee of the ICS. Neurourol Urodyn. 2002; 21(2): 167-78.
2. Wu JM, Vaughan CP, Goode PS et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123: 141-8.
3. Milsom I, Altman D, Cartwright R et al. Epidemiology of urinary incontinence and other lower urinary tract symptoms, pelvic organ prolapse and anal incontinence. International Continence Society, Bristol 2017.
4. Brown JS, Vittinghoff E, Wyman JF et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000; 48(7): 721-5.
5. Minassian VA, Hagan KA, Erekson E et al. The natural history of urinary incontinence subtypes in the Nurses’ Health Studies. Am J Obstet Gynecol. 2020; 222(2): 163.e1-163e.8.
6. Kelleher CJ, Kreder KJ, Pleil AM et al. Longterm health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care. 2002; 8: S616-S30.
7. Sacco E, Tienforti D, D’Addessi A et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol. 2010; 2: 11-24.
8. Sacco E. Physiopathology of overactive bladder syndrome. Urologia. 2012; 79(1): 24-35.
9. Tadic SD, Griffiths D, Schaefer W et al. Brain activity underlying impaired continence control in older women with overactive bladder. Neurourol Urodyn. 2012; 31(5): 652-8.
10. Ketai LH, Komesu YM, Dodd AB et al. Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol. 2016; 215(4): 449.e1-449.e17.
11. Brading A, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. Adv Exp Med Biol. 2003; 539(Pt A): 255-69.
12. Yoshida M, Miyamae K, Iwashita H et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004; 63(3 suppl 1): 17-23.
13. Iosif S, Batra S, Ek A et al. Estrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol. 1981; 141(7): 817-20.
14. Robinson D, Cardoza L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodynam. 2014; 33(7): 1086-91.
15. Gomez-Amaya SM, Ruggieri MR, Arias Serrato SA et al. Gross anatomical study of the nerve supply of genitourinary structures in female mongrel hound dogs. Anat Histol Embryol. 2014; 44: 118-27.
16. Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29: 4-20.
17. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
18. Enck P, Aziz Q, Barbara G et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016; 2: 16014.
19. Li M, Sun Y, Simard JM et al. Increased transient receptor potential vanilloid type 1 (TRPV1) signaling in idiopathic overactive bladder urothelial cells. Neurourol Urodyn. 2011; 30: 606-11.
20. Burgio KL. Update on behavioral and physical therapies for incontinence and overactive bladder: the role of pelvic floor muscle training. Curr Urol Rep. 2013; 14(5): 457-64.
21. Fonda D, Abrams P. Cure sometimes, help always – a “continence paradigm” for all ages and conditions. Neurourol Urodyn. 2006; 25(3): 290-2.
22. Tak EC, van Hespen A, van Dommelen P et al. Does improved functional performance help to reduce urinary incontinence in institutionalized older women? A multicenter randomized clinical trial. BMC Geriatr. 2012; 12: 51.
23. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002; 288(18): 2293-9.
24. Griffiths D, Clarkson B, Tadic SD et al. Brain Mechanisms Underlying Urge Incontinence and its Response to Pelvic Floor Muscle Training. J Urol. 2015; 194(3): 708-15.
25. Fox C, Richardson K, Maidman I et al. Anticholinergic medication and use and cognitive impairment in the older population: the medical research council cognitive function and aging study. J Am Geriatr Soc. 2011; 59(8): 1477-83.
26. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol. 1984; 11(1-2): 37-42.
27. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007; 52(4): 1204-12. http://doi.org/10.1016/j.eururo.2007.07.009.
28. Sexton CC, Notte SM, Maroulis C et al. Persistence and adherence in the t reatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5): 567-85. http://doi.org/10.1111/j.1742-1241.2010.02626.x.
29. Wagg A, Dale M, Tretter R et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013; 64(1): 74-81. http://doi.org/10.1016/j.eururo.2013.01.002.
30. Rosa G, Ferrero S, Nitti V et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder. Eur Urol. 2016; 69(2): 311-23.
31. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26(6): 752-6.
32. Wagg A. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging. 2012; 29(7): 539-48.
33. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012; 31(8): 1206-16.
34. Averbeck MA, Gomes CM. Worldwide Utilization Patterns of Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction. Current Bladder Dysfunction Reports. 2016; 11: 356-64.
35. Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge incontinent population. Am J Obstet Gynecol. 2002; 187(6): 1462-5.
36. Miotla P, Cartwright R, Skorupska K et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk. Int Urogynecol J. 2017; 28(6): 845-50.
37. Liao C, Kuo H. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013; 189(5): 1804-10.
2. Wu JM, Vaughan CP, Goode PS et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123: 141-8.
3. Milsom I, Altman D, Cartwright R et al. Epidemiology of urinary incontinence and other lower urinary tract symptoms, pelvic organ prolapse and anal incontinence. International Continence Society, Bristol 2017.
4. Brown JS, Vittinghoff E, Wyman JF et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000; 48(7): 721-5.
5. Minassian VA, Hagan KA, Erekson E et al. The natural history of urinary incontinence subtypes in the Nurses’ Health Studies. Am J Obstet Gynecol. 2020; 222(2): 163.e1-163e.8.
6. Kelleher CJ, Kreder KJ, Pleil AM et al. Longterm health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care. 2002; 8: S616-S30.
7. Sacco E, Tienforti D, D’Addessi A et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol. 2010; 2: 11-24.
8. Sacco E. Physiopathology of overactive bladder syndrome. Urologia. 2012; 79(1): 24-35.
9. Tadic SD, Griffiths D, Schaefer W et al. Brain activity underlying impaired continence control in older women with overactive bladder. Neurourol Urodyn. 2012; 31(5): 652-8.
10. Ketai LH, Komesu YM, Dodd AB et al. Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol. 2016; 215(4): 449.e1-449.e17.
11. Brading A, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. Adv Exp Med Biol. 2003; 539(Pt A): 255-69.
12. Yoshida M, Miyamae K, Iwashita H et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004; 63(3 suppl 1): 17-23.
13. Iosif S, Batra S, Ek A et al. Estrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol. 1981; 141(7): 817-20.
14. Robinson D, Cardoza L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodynam. 2014; 33(7): 1086-91.
15. Gomez-Amaya SM, Ruggieri MR, Arias Serrato SA et al. Gross anatomical study of the nerve supply of genitourinary structures in female mongrel hound dogs. Anat Histol Embryol. 2014; 44: 118-27.
16. Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29: 4-20.
17. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
18. Enck P, Aziz Q, Barbara G et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016; 2: 16014.
19. Li M, Sun Y, Simard JM et al. Increased transient receptor potential vanilloid type 1 (TRPV1) signaling in idiopathic overactive bladder urothelial cells. Neurourol Urodyn. 2011; 30: 606-11.
20. Burgio KL. Update on behavioral and physical therapies for incontinence and overactive bladder: the role of pelvic floor muscle training. Curr Urol Rep. 2013; 14(5): 457-64.
21. Fonda D, Abrams P. Cure sometimes, help always – a “continence paradigm” for all ages and conditions. Neurourol Urodyn. 2006; 25(3): 290-2.
22. Tak EC, van Hespen A, van Dommelen P et al. Does improved functional performance help to reduce urinary incontinence in institutionalized older women? A multicenter randomized clinical trial. BMC Geriatr. 2012; 12: 51.
23. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002; 288(18): 2293-9.
24. Griffiths D, Clarkson B, Tadic SD et al. Brain Mechanisms Underlying Urge Incontinence and its Response to Pelvic Floor Muscle Training. J Urol. 2015; 194(3): 708-15.
25. Fox C, Richardson K, Maidman I et al. Anticholinergic medication and use and cognitive impairment in the older population: the medical research council cognitive function and aging study. J Am Geriatr Soc. 2011; 59(8): 1477-83.
26. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol. 1984; 11(1-2): 37-42.
27. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007; 52(4): 1204-12. http://doi.org/10.1016/j.eururo.2007.07.009.
28. Sexton CC, Notte SM, Maroulis C et al. Persistence and adherence in the t reatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5): 567-85. http://doi.org/10.1111/j.1742-1241.2010.02626.x.
29. Wagg A, Dale M, Tretter R et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013; 64(1): 74-81. http://doi.org/10.1016/j.eururo.2013.01.002.
30. Rosa G, Ferrero S, Nitti V et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder. Eur Urol. 2016; 69(2): 311-23.
31. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26(6): 752-6.
32. Wagg A. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging. 2012; 29(7): 539-48.
33. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012; 31(8): 1206-16.
34. Averbeck MA, Gomes CM. Worldwide Utilization Patterns of Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction. Current Bladder Dysfunction Reports. 2016; 11: 356-64.
35. Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge incontinent population. Am J Obstet Gynecol. 2002; 187(6): 1462-5.
36. Miotla P, Cartwright R, Skorupska K et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk. Int Urogynecol J. 2017; 28(6): 845-50.
37. Liao C, Kuo H. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013; 189(5): 1804-10.